Summarized by Masters of Longevity from Longevity Technology.
A healthcare partnership story about building a combined blood biomarker and digital cognitive testing pathway to speed and simplify Alzheimer’s diagnostics.
Key Takeaways
- C2N Diagnostics will integrate its MHRA-registered blood test with digital cognitive assessments and national imaging services in the UK.
- The combined blood biomarker and digital test reportedly reached about 90% accuracy versus typical GP accuracy near 70% in validation analyses.
- UK clinicians will be able to order the blood test and cognitive assessments through The Alzheimer’s Trust to streamline diagnostic referrals.
